|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 221 CHF | +1.01% |
|
+0.45% | -9.61% |
| 02:32pm | Roche: positive CHMP opinion for Alecensa | CF |
| 01:58pm | Roche’s Lung Cancer Drug Alecensa Backed for Approval in EU | MT |
By Mauro Orru
Roche Holding AG said Friday that data from a pivotal Phase 3 study shows that Alecensa has a higher five-year survival rate than crizotinib for people living with anaplastic lymphoma kinase-positive non-small cell lung cancer.
The Swiss drugmaker said data showed a five-year survival rate of 62.5% with Alecensa, compared with 45.5% for crizotinib.
Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94
| 1st Jan change | Capi. | |
|---|---|---|
| -9.61% | 193B | |
| +25.83% | 653B | |
| +27.00% | 556B | |
| -6.76% | 354B | |
| +20.34% | 331B | |
| +3.00% | 296B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -6.26% | 144B | |
| -11.77% | 143B |
ROCHE HOLDING AG 
